Inhibition of bone resorption and growth of breast cancer in the bone microenvironment

Bone

Volumn 44, Issue 2, 2009, Pages 380-386

  Buijs, Jeroen T ^a   Que, Ivo ^a   Löwik, Clemens W G M ^a   Papapoulos, Socrates E ^a   van der Pluijm, Gabri ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone metastasis; Bone turnover; Breast cancer; Osteoprotegerin; Zoledronic acid

Indexed keywords

OSTEOPROTEGERIN; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE ATROPHY; BONE DESTRUCTION; BONE TUMOR; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; MICROENVIRONMENT; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; RADIOGRAPHY; TIBIA; TRABECULAR BONE; TUMOR VOLUME;

ACID PHOSPHATASE; ANIMALS; BONE AND BONES; BONE RESORPTION; BREAST NEOPLASMS; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; ISOENZYMES; LUMINESCENT MEASUREMENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; WHOLE BODY IMAGING;

EID: 58249121577     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.10.047     Document Type: Article

References (50)

1. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2 (2002) 584-593
2. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1 (1889) 571-573
3. Clines G.A., and Guise T.A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer 12 (2005) 549-583
4. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
5. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J. Clin. 56 (2006) 106-130
6. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 (1997) 1-18
7. Arguello F., Baggs R.B., Graves B.T., Harwell S.E., Cohen H.J., and Frantz C.N. Effect of IL-1 on experimental bone/bone-marrow metastases. Int. J. Cancer 52 (1992) 802-807
8. Kostenuik P.J., Singh G., Suyama K.L., and Orr F.W. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin. Exp. Metastasis 10 (1992) 411-418
9. Schneider A., Kalikin L.M., Mattos A.C., Keller E.T., Allen M.J., Pienta K.J., et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146 (2005) 1727-1736
10. Brown J.E., Cook R.J., Major P., Lipton A., Saad F., Smith M., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97 (2005) 59-69
11. Costa L., Demers L.M., Gouveia-Oliveira A., Schaller J., Costa E.B., de Moura M.C., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. 20 (2002) 850-856
12. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55 (1995) 3551-3557
13. van der Pluijm G., Que I., Sijmons B., Buijs J.T., Lowik C.W., Wetterwald A., et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 65 (2005) 7682-7690
14. Hiraga T., Williams P.J., Ueda A., Tamura D., and Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 10 (2004) 4559-4567
15. Sasaki A., Kitamura K., Alcalde R.E., Tanaka T., Suzuki A., Etoh Y., et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int. J. Cancer 77 (1998) 279-285
16. Daubine F., Le Gall C., Gasser J., Green J., and Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl. Cancer Inst. 99 (2007) 322-330
17. Wetterwald A., van der Pluijm G., Que I., Sijmons B., Buijs J., Karperien M., et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am. J. Pathol. 160 (2002) 1143-1153
18. van der Pluijm G., Sijmons B., Vloedgraven H., van der Bent C., Drijfhout J.W., Verheijen J., et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. 159 (2001) 971-982
19. Morony S., Capparelli C., Lee R., Shimamoto G., Boone T., Lacey D.L., et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res. 14 (1999) 1478-1485
20. van der Pluijm G., Sijmons B., Vloedgraven H., Deckers M., Papapoulos S., and Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J. Bone Miner. Res. 16 (2001) 1077-1091
21. Alakangas A., Selander K., Mulari M., Halleen J., Lehenkari P., Monkkonen J., et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif. Tissue Int. 70 (2002) 40-47
22. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
23. Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin. Oncol. 28 (2001) 35-44
24. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
25. Hill P.A. Bone remodelling. Br. J. Orthod. 25 (1998) 101-107
26. Guise T.A., and Mundy G.R. Cancer and bone. Endocr. Rev. 19 (1998) 18-54
27. Vaananen K. Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 57 (2005) 959-971
28. Michaelson M.D., and Smith M.R. Bisphosphonates for treatment and prevention of bone metastases. J. Clin. Oncol. 23 (2005) 8219-8224
29. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
30. Coleman R.E. Bisphosphonates in breast cancer. Ann. Oncol. 16 (2005) 687-695
31. Elte J.W., Bijvoet O.L., Cleton F.J., van Oosterom A.T., and Sleeboom H.P. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur. J. Cancer Clin. Oncol. 22 (1986) 493-500
32. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 (2000) 1082-1090
33. Body J.J., Diel I.J., Lichinitser M.R., Kreuser E.D., Dornoff W., Gorbunova V.A., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14 (2003) 1399-1405
34. Powles T., Paterson A., McCloskey E., Schein P., Scheffler B., Tidy A., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 8 (2006) R13
35. Rosen L.S., Gordon D.H., Dugan Jr. W., Major P., Eisenberg P.D., Provencher L., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100 (2004) 36-43
36. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., and Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82 (2000) 1459-1468
37. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H., and Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84 (2001) 1126-1134
38. Fromigue O., Lagneaux L., and Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15 (2000) 2211-2221
39. Peyruchaud O., Winding B., Pecheur I., Serre C.M., Delmas P., and Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J. Bone Miner. Res. 16 (2001) 2027-2034
40. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10 (1995) 1478-1487
41. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
42. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3597-3602
43. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
44. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15 (2004) 457-475
45. Blair J.M., Zhou H., Seibel M.J., and Dunstan C.R. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat. Clin. Pract. Oncol. 3 (2006) 41-49
46. Croucher P.I., Shipman C.M., Van Camp B., and Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 97 (2003) 818-824
47. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., and Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61 (2001) 4432-4436
48. Morony S., Warmington K., Adamu S., Asuncion F., Geng Z., Grisanti M., et al. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146 (2005) 3235-3243
49. Zheng Y., Zhou H., Brennan K., Blair J.M., Modzelewski J.R., Seibel M.J., et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40 (2007) 471-478
50. Canon J.R., Roudier M., Bryant R., Morony S., Stolina M., Kostenuik P.J., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25 (2007) 119-129